Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02435212
Other study ID # CICL670F2202
Secondary ID 2013-004739-55
Status Completed
Phase Phase 2
First received
Last updated
Start date October 21, 2015
Est. completion date January 15, 2024

Study information

Verified date March 2024
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance and change in serum ferritin of a deferasirox granule formulation and a deferasirox DT formulation in children and adolescents aged ≥ 2 and < 18 years at enrollment with any transfusion-dependent anemia requiring chelation therapy due to iron overload, to demonstrate the effect of improved compliance on iron burden. Randomization will be stratified by age groups (2 to <10 years, 10 to <18 years) and prior iron chelation therapy (Yes/ No). There will be two study phases which include a 1 year core phase where patients will be randomized to a 48 week treatment period to either Deferasirox DT or granules, and an optional extension phase where all patients will receive the granules up to 5 years. Patients who demonstrated benefit to granules or DT in the core phase, and/or express the wish to continue in the optional extension phase on granules, will be offered this possibility until there is local access to the new formulation (granules or FCT) or up to 5 years, whichever occurs first.


Recruitment information / eligibility

Status Completed
Enrollment 224
Est. completion date January 15, 2024
Est. primary completion date May 31, 2018
Accepts healthy volunteers No
Gender All
Age group 2 Years to 17 Years
Eligibility Inclusion Criteria: - Written informed consent/assent before any study-specific procedures. Consent will be obtained from parent(s) or legal guardians. Investigators will also obtain assent of patients according to local guidelines. - Male and female children and adolescents aged = 2 and < 18 years. [France: Male and female children and adolescent aged = 2 and < 18 years old, however children aged = 2 and = 6years can be enrolled only when deferoxamine treatment is contraindicated or inadequate in these patients as per investigator decision. Applicable to core phase only. Once in the core phase patients can turn 18 years and still be considered eligible, also for participation in the optional extension phase. - Any transfusion-dependent anemia associated with iron overload requiring iron chelation therapy and with a history of transfusion of approximately 20 PRBC units and a treatment goal to reduce iron burden (300mL PRBC = 1 unit in adults whereas 4 ml/kg PRBC is considered 1 unit for children). - Serum ferritin > 1000 ng/mL, measured at screening Visit 1 and screening Visit 2 (the mean value will be used for eligibility criteria). - Patient has to have participated and completed the 48 weeks core phase treatment as per protocol (For optional extension phase eligibility only). Exclusion Criteria: - Creatinine clearance below the contraindication limit in the locally approved prescribing information (using Schwartz formula) at screening visit 1 or screening visit 2. - Serum creatinine > 1.5 xULN at screening measured at screening Visit 1 and or screening Visit 2 - ALT and/or AST > 3.0 x ULN at screening visit 1 or screening visit 2.. - Liver disease with severity of Child-Pugh class B or C. - Significant proteinuria as indicated by a urinary protein/creatinine ratio > 0.5 mg/mg in a second morning urine sample at screening Visit 1 or screening Visit 2. - Patients with significant impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral deferasirox (e.g. ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection). - Direct (conjugated) bilirubin >2 x ULN at screening visit 1 or screening visit 2. - Local access to new formulation (granules or FCT) is available (For optional extension phase eligibility only). Other protocol-defined Inclusion/Exclusion may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Deferasirox granule formulation
Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use.
Deferasirox DT formulation
Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use

Locations

Country Name City State
Belgium Novartis Investigative Site Brussel
Belgium Novartis Investigative Site Edegem Antwerpen
Bulgaria Novartis Investigative Site Plovdiv
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Varna
Egypt Novartis Investigative Site Alexandria
France Novartis Investigative Site Creteil
France Novartis Investigative Site Paris 15
Hungary Novartis Investigative Site Debrecen
India Novartis Investigative Site Kolkata West Bengal
Italy Novartis Investigative Site Genova GE
Italy Novartis Investigative Site Napoli
Italy Novartis Investigative Site Palermo PA
Italy Novartis Investigative Site Palermo PA
Lebanon Novartis Investigative Site Hazmiyeh Beirut
Malaysia Novartis Investigative Site Ipoh Perak
Malaysia Novartis Investigative Site Kuala Lumpur
Malaysia Novartis Investigative Site Kuching Sarawak
Malaysia Novartis Investigative Site Pulau Pinang
Oman Novartis Investigative Site Muscat
Panama Novartis Investigative Site Panama City Republica De Panama
Philippines Novartis Investigative Site Quezon City
Russian Federation Novartis Investigative Site Moscow
Thailand Novartis Investigative Site Bangkok noi Bangkok
Thailand Novartis Investigative Site Muang Chiangmai
Tunisia Novartis Investigative Site Tunis
Turkey Novartis Investigative Site Adana
Turkey Novartis Investigative Site Ankara
Turkey Novartis Investigative Site Izmir
United States Novartis Investigative Site Atlanta Georgia
United States Childrens Hospital at Montefiore Bronx New York
United States Medical Uni of South Carolina Medical Uni of South Carolina Charleston South Carolina
United States Novartis Investigative Site Chicago Illinois
United States St. Jude Children's Research Hospital Memphis St Jude Memphis Tennessee
United States Weill Cornell Medical College SC - New York New York
United States Novartis Investigative Site Oakland California
United States Childrens Hospital of Philadelphia Onc. Dept Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Belgium,  Bulgaria,  Egypt,  France,  Hungary,  India,  Italy,  Lebanon,  Malaysia,  Oman,  Panama,  Philippines,  Russian Federation,  Thailand,  Tunisia,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Compliance (using stick/pack tablet count). Evaluate patient compliance measured by stick pack/tablet count in ICT naïve patients during core phase. 24 weeks
Primary Change in serum ferritin in ICT naive patients. The comparison of means between the two treatment arms of change from baseline to week 24 of treatment in serum ferritin in pediatric ICT naïve patients with iron overload. From Baseline to 24 weeks
Secondary Compliance (using stick/pack tablet count) Evaluate patient compliance measured by stick pack/tablet count in ICT naïve patients during core phase. 48 weeks
Secondary Change in serum ferritin in ICT naive patients The comparison of means between the two treatment arms of change from baseline to week 48 week of treatment in serum ferritin in pediatric ICT naïve patients with iron overload. From Baseline to 48 weeks
Secondary Change in serum ferritin in pre-treated patients The comparison of means between the two treatment arms of change from baseline to week 24 and to 48 weeks of treatment in serum ferritin in pre-treated patients. From Baseline to 24 weeks and 48 weeks
Secondary Domain scores of treatment satisfaction and palatability over time To evaluate both formulations on patient satisfaction and palatability using Patient / Observer Reported Outcomes (PRO/ObsRO) questionnaires From baseline to 48 weeks
Secondary Overall safety, as measured by frequency and severity of adverse This includes active monitoring for renal toxicity; including renal failure, hepatic toxicity; including hepatic failure, and gastrointestinal hemorrhage), and changes in laboratory values from baseline (serum creatinine, creatinine clearance, ALT, AST, RBC and WBC). In addition, vital signs, physical, ophthalmological, audiometric, cardiac, and growth and development evaluations will be assessed. From Baseline to 48 weeks
Secondary Rate of dosing instructions deviations ('Compliance', using a questionnaire) This includes doses missed/not taken at the same time every day, to evaluate the compliance using a daily PRO/ObsRO questionnaire. From Baseline to 48 weeks
Secondary Pre-dose deferasirox concentrations in all patients The pre-dose concentration by incident dose will be plotted for Week 1, Week 3, Week 5, Week 9, Week 13, Week 17, Week 21, Week 25, Week 29, Week 33, Week, 37, Week 41 and Week 45 based on data from all patients. Pre-dose PK data from all patients will be analyzed to support the assessment of compliance.Predicted individual concentrations derived from the compartmental model will be compared to respective observed pre-dose concentrations. Distributions of the difference between predicted and observed values will be shown graphically by boxplots for both treatment groups and visit. at Weeks 1, 3, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, and 45 (13 samples)
Secondary Post-dose deferasirox concentrations between 2 and 4 hours post-dose at Weeks 5 and 9 post-dose PK data to be analyzed along with pre-dose PK data Week 5, Week 9
Secondary PK/PD relationship To explore exposure-response relationships for measures of safety and effectiveness: serum creatinine change from baseline, notable serum creatinine values, serum creatinine clearance change from baseline and notable serum creatinine clearance categories, serum ferritin change from baseline, in relationship to derived PK parameters for pre- and post-dose deferasirox concentrations. From Baseline to 48 weeks
Secondary Assess additional safety, as measured by frequency and severity of adverse for granules during extension phase This includesactive monitoring for renal toxicity; including renal failure, hepatic toxicity; including hepatic failure, and gastrointestinal hemorrhage), and changes in laboratory values from baseline (serum creatinine, creatinine clearance, ALT, AST, RBC and WBC). In addition, vital signs, physical, ophthalmological, audiometric, and growth and development evaluations will be assessed. From Baseline to 305 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05924100 - Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD Phase 2
Completed NCT04303910 - An Analysis of Blood Management in Patients Having Hip or Knee Arthroplasty
Terminated NCT03643042 - Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic Syndrome N/A
Completed NCT04856618 - Machine Learning-Based Prediction of Major Perioperative Allogeneic Blood Requirements in Cardiac Surgery
Not yet recruiting NCT06414031 - Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery Phase 3
Recruiting NCT05462548 - The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study Phase 4
Completed NCT05466370 - Prediction of Transfusion-Associated Complications
Completed NCT04155021 - Knowledge and Attitude in Perioperative Erythrocyte Transfusion in Medical Personnel in Siriraj Hospital
Active, not recruiting NCT05739097 - Prospective Study on Feto-maternal outcoMe In aNemIc womEn
Completed NCT05203016 - Complications Associated With Intraoperative Hypothermia.
Recruiting NCT03369210 - Liberal Transfusion Strategy in Elderly Patients Phase 3